Efficacy and Safety of Compound Kushen Injection Used for Peritoneal Perfusion on Patients with Malignant Ascites / 中国中医药信息杂志

ABSTRACT

Objective To observe the clinical efficacy and safety of compound Kushen Injection in the patients with malignant ascites. Methods Totally 139 patients with malignant ascites were randomly divided into treatment group and control group. 30 mL compound Kushen Injection was given to the treatment group, and 100 mg cisplatin was given to the control group through peritoneal perfusion once a week, for 3 weeks. The changes of urine volume, abdominal perimeter, blood-Rt, function of liver and kidney, and gastrointestinal reaction were detected before and after treatment, with a purpose to evaluate the total efficacy and safety. Results The total effective rate was 80.56% (58/72) in treatment group, and 86.57% (58/67) in the control group, without significant difference between the two groups. The incidences of bone marrow suppression, liver and kidney damage, and nausea and vomiting of gastrointestinal reaction were lower in the treatment group than the control group. Conclusion The effects of compound Kushen Injection and cisplatin have equal efficacy for the treatment of malignant ascites, but the former was superior to the latter on safety.